GO
Loading...

Merck & Co Inc

More

  • *Q4 sales $6.84 bln vs consensus $6.88 bln. *Q4 core earnings per share $1.23 vs consensus $1.16. LONDON, Feb 6- AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from late May.

  • *Q4 core earnings per share $1.23 vs $1.16. LONDON, Feb 6- AstraZeneca expects earnings to continue to fall in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from May. Shares in AstraZeneca fell 1 percent in early trading.

  • For example, the price discussed for 24 weeks of Sovaldi therapy would run about $2,500 for certain patients at public hospitals, community clinics and non-governmental agencies in India, the Hindu Business Line reported earlier this week.

  • US stocks slightly off; little moved by data, earnings Wednesday, 5 Feb 2014 | 4:00 PM ET

    Stocks fell on Wednesday after data had companies adding fewer employees to their payrolls than anticipated.

  • Yields tick higher, T-bills hurt by debt ceiling Wednesday, 5 Feb 2014 | 2:42 PM ET

    U.S. bonds edged lower on Wednesday, with yields rising after private payroll data missed market expectations.

  • US stock futures clear bulk of losses after ADP report Wednesday, 5 Feb 2014 | 9:00 AM ET

    U.S. stock index futures signaled a lower open on Wednesday, as Wall Street considered the ADP employment report.

  • Feb 5- Merck& Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but shares rose 1.5 percent on enthusiasm for newly announced cancer-drug partnerships with rival U.S. companies.

  • Cheaper generics hit Merck fourth-quarter profit Wednesday, 5 Feb 2014 | 8:36 AM ET
    Merck sign in front of the company's building on October 2, 2013 in Summit, New Jersey.

    Merck reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.

  • GSK optimistic as sales beat forecasts Wednesday, 5 Feb 2014 | 8:31 AM ET
    A bottle and pills of the diabetes drug, Avandia.

    GSK said sales rose five percent in the fourth quarter of last year, narrowly beating expectations and indicating that the U.K. pharmaceutical giant's fortunes may be picking up.

  • Early movers: MRK, TWX, UA, SNE, GOOG, BWLD & more Wednesday, 5 Feb 2014 | 7:34 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Feb 5- Merck& Co Inc reported quarterly sales that were slightly lower than expected, hurt by competition from cheaper generic medicines, and predicted full-year earnings at the lower end of analysts' expectations. The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter.

  • Merck 4th-quarter sales just miss Wall St estimate Wednesday, 5 Feb 2014 | 7:13 AM ET

    Feb 5- Merck& Co Inc reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines. The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter. Wall Street was expecting $11.36 billion, according to Thomson Reuters I/B/E/S.

  • Traders watch data to see if weakness a ‘blip’ Tuesday, 4 Feb 2014 | 6:55 PM ET
    Traders on the floor of the New York Stock Exchange.

    ADP's private sector jobs report and data on services sector activity could set the direction for stocks Wednesday.

  • *Ablynx initially to get 20 mln euros, plus 10.7 mln for research. *Ablynx shares gain up to 6.9 pct. BRUSSELS, Feb 3- Belgian biotech company Ablynx has signed a deal with Merck& Co worth up to 1.7 billion euros to develop ways of triggering the body to fight cancer by itself.

  • More bumps ahead as market awaits big report Friday, 31 Jan 2014 | 7:03 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Traders await Friday's jobs report and watch emerging markets to see if the selloff can be contained.

  • Cramer believes there’s always opportunity in the market. You simply have to know where to look.

  • Squawking Henny Youngman, supermodels, selloff Thursday, 30 Jan 2014 | 11:46 AM ET
    Henny Youngman in 1992

    Talking Squawk, the "Squawk Box" blog, provides tidbits, insights and sarcastic reflections on the WEEK THAT WAS and the WEEK TO COME.

  • INTERVIEW-Lilly CEO: 'It's time to go back on offense' Wednesday, 29 Jan 2014 | 3:50 PM ET

    Jan 29- After three years of seeing major drugs like Zyprexa for schizophrenia lose patent protection and wipe away billions of dollars in revenue, Eli Lilly and Co Chief Executive Officer John Lechleiter wants to change the game plan.

  • BASEL, Jan 29- Novartis is looking at options, such as joint ventures, for three smaller businesses to bring them in line with its world-leading pharmaceutical operations, it said on Wednesday, in a review due to be completed by the end of summer.

  • Jan 28- Merck& Co's experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday. About 30 million people in the United States suffer allergies to ragweed pollen, according to the FDA.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.